Keep an eye on rebounding shares of Viking Therapeutics (VKTX).

Earlier this year, the company reported that the injectable form of its obesity treatment helped patients lose up to 13.1% of their weight after 13 weeks. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials. That tablet form of the treatment is expected to enter Phase 2 trials in the second half of the year.

Should we see even more solid trial data for both treatments, VKTX could rally to more than $95 again. Better, further success could expose VKTX to a massive market.

Right now, according to the World Health Organization, obesity has tripled since 1975.  

More than 1.9 billion adults were overweight, as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweight in 2016, as well.  It’s an issue that’s been plaguing society for quite some time.  Worse, by 2030, about 20% of the global population will be obese, according to the National Centers for Biotechnology Information.  

And, as noted by Goldman Sachs, “Earlier this year, the global market for anti-obesity medications (AOMs) reached $6 billion on an annualized basis. By 2030, it could grow by more than 16 times to $100 billion, according to Goldman Sachs Research.”